Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Analysts at Jefferies Financial Group upped their FY2022 earnings per share estimates for shares of Spring Bank Pharmaceuticals in a research report issued on Sunday, November 10th. Jefferies Financial Group analyst M. Raycroft now forecasts that the company will earn $2.73 per share for the year, up from their prior forecast of $2.68. Jefferies Financial Group also issued estimates for Spring Bank Pharmaceuticals’ FY2023 earnings at $5.28 EPS.
Other equities analysts have also issued reports about the company. B. Riley cut their price target on Spring Bank Pharmaceuticals from $24.00 to $16.00 and set a “buy” rating for the company in a report on Monday, August 5th. Zacks Investment Research downgraded Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 5th. Finally, ValuEngine raised Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.80.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last announced its earnings results on Thursday, November 7th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.19.
Several hedge funds have recently added to or reduced their stakes in SBPH. Acadian Asset Management LLC purchased a new stake in shares of Spring Bank Pharmaceuticals during the second quarter worth about $29,000. Arcadia Investment Management Corp MI acquired a new position in Spring Bank Pharmaceuticals in the 2nd quarter valued at about $44,000. Jane Street Group LLC acquired a new position in Spring Bank Pharmaceuticals in the 2nd quarter valued at about $59,000. Susquehanna International Group LLP acquired a new position in Spring Bank Pharmaceuticals in the 2nd quarter valued at about $91,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Spring Bank Pharmaceuticals by 35.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 25,064 shares of the company’s stock worth $98,000 after acquiring an additional 6,565 shares during the last quarter. 41.90% of the stock is owned by institutional investors and hedge funds.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).
Featured Article: Catch-Up Contributions
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.